
Roche Positioned as Defensive Healthcare Anchor in 2026 Portfolio Strategy
Roche offers defensive 2026 portfolio appeal with 7% sales growth and 13% profit growth, emphasizing stability over explosive expansion through diversified healthcare exposure.
RHHBYoperating marginspharmaceutical